Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 18/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198050 | 0.91 | MAPK1 (0.44) | IDH1CALCRLENPP1 | |
| Hydrochloric Acid SCHEMBL2322170 | 0.90 | MAPK1 (0.43) | IDH1CALCRLENPP1 | |
| SCHEMBL27305349 | 0.90 | CHRM2 (0.44) | IDH1CALCRL | |
| SCHEMBL13801274 | 0.87 | CALCRL (0.44) | IDH1CALCRL | |
| SCHEMBL23257321 | 0.86 | PARP2 (0.47) | IDH1CALCRL | |
| SCHEMBL2214219 | 0.86 | CALCRL (0.51) | IDH1CALCRL | |
| SCHEMBL5242632 | 0.86 | CALCRL (0.43) | IDH1CALCRL | |
| SCHEMBL14410176 | 0.86 | PARP1 (0.47) | IDH1CALCRL | |
| SCHEMBL3956507 | 0.83 | CHRM4 (0.52) | — | |
| SCHEMBL12080852 | 0.80 | HTR2A (0.39) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| WO-2010103306-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS | ASTRAZENECA UK LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | IDH1 3132/4885CALCRL 3162/4885ENPP1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.